ClinicalTrials.gg

Program

Palforzia

Also written as “DBV712 250 mcg”, “DBV712” and “Viaskin Peanut 250mcg”.

Its studies are mostly in Peanut Hypersensitivity, led by DBV Technologies.

Furthest: phase 3, since Nov 19, 20155 company-led studies, 2 open or runningNext primary completion: Nov 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
DBV Technologies52 open or runningphase 3since Nov 19, 2015Nov 19, 2015Nov 2026phase 3 · NCT07003919

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 19, 2015First study: phase 3 study in Peanut HypersensitivityFirst studyNCT02636699 · 500 enrolled · United States, Australia, Canada and more
  2. Nov 21, 2017Phase 1 study in Peanut HypersensitivityNCT03352726 · 27 enrolled · United States
  3. Feb 19, 2019Phase 3 study in Peanut HypersensitivityNCT03859700 · 304 enrolled · United States
  4. Feb 14, 2023Phase 3 study in Peanut HypersensitivityNCT05741476 · 600 enrolled · United States, Australia, Canada and more
  5. May 27, 2025Phase 3 study in HypersensitivityNCT07003919 · 480 enrolled · United States, Australia, Canada and more

Ahead

  1. Nov 2026Primary completion: phase 3 study in HypersensitivityNCT07003919

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07003919Hypersensitivity · United States, Australia, Canada and more3Active, not recruitingNov 2026480
NCT05741476Peanut Hypersensitivity · United States, Australia, Canada and more3Active, not recruitingNov 6, 2025600
NCT03859700Peanut Hypersensitivity · United States3CompletedMay 13, 2025304
NCT03352726Peanut Hypersensitivity · United States1CompletedJun 29, 201827
NCT02636699Peanut Hypersensitivity · United States, Australia, Canada and more3CompletedAug 18, 2017500

How it is read

Names in the registry

  • “DBV712 250 mcg”, 2 entries
  • “DBV712”, 2 entries
  • “Viaskin Peanut 250mcg”, 1 entry
  • “DBV712 IHRP”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.